Abstract
In this report, we present a new strategy for targeting chemotherapeutics to tumors, based on targeting extracellular DNA. A gemcitabine prodrug was synthesized, termed H-gemcitabine, which is composed of Hoechst conjugated to gemcitabine. H-gemcitabine has low toxicity because it is membrane-impermeable; however, it still has high tumor efficacy because of its ability to target gemcitabine to E-DNA in tumors. We demonstrate here that H-gemcitabine has a wider therapeutic window than free gemcitabine.
Original language | British English |
---|---|
Pages (from-to) | 4-8 |
Number of pages | 5 |
Journal | Bioconjugate Chemistry |
Volume | 24 |
Issue number | 1 |
DOIs | |
State | Published - 16 Jan 2013 |